JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations
Clinical trial NCT06380348 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06380348
- Sponsor
- Shanghai JMT-Bio Inc.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-26
- Primary completion
- 2027-03-26
- Enrollment
- 398
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.